Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Clarke CS, Hunter RM, Gabrio A, Brawley CD, Ingleby FC, Dearnaley DP, Matheson D, Attard G, Rush HL, Jones RJ, Cross W, Parker C, Russell JM, Millman R, Gillessen S, Malik Z, Lester JF, Wylie J, Clarke NW, Parmar MKB, Sydes MR, James ND.
Clarke CS, et al. Among authors: hunter rm.
PLoS One. 2022 Jun 2;17(6):e0269192. doi: 10.1371/journal.pone.0269192. eCollection 2022.
PLoS One. 2022.
PMID: 35653395
Free PMC article.
Clinical Trial.